Endometrial Carcinoma | Unmet Need | Advanced or Recurrent Endometrial Carcinoma | US/EU | 2022
Immune checkpoint inhibitors, such as Merck & Co.’s Keytruda and GlaxoSmithKline’s Jemperli, and targeted therapies, such as Eisai’s Lenvima, have revolutionized the therapeutic landscape of advanced or recurrent endometrial carcinoma, for which chemotherapy and hormonal therapy used to be the standard of care. Nevertheless, treatment options are limited in later lines of therapy and there remains a pressing need for more-effective treatments in the advanced or recurrent setting. We assess how current therapies perform on key drug attributes and measure the impact of drug attributes on physicians’ prescribing behavior for advanced or recurrent endometrial carcinoma. We also identify potential hidden opportunities emerging therapies could capitalize upon.
QUESTIONS ANSWERED
- What are the treatment drivers and goals in medical oncologists’ prescribing decisions in advanced or recurrent endometrial carcinoma? What are the hidden opportunities that developers could leverage?
- How do key current therapies, such as immune checkpoint inhibitors, perform on key clinical attributes for this patient population?
- What are the greatest unmet needs and most attractive opportunities for advanced or recurrent endometrial carcinoma?
- What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in June 2022
Key companies: Merck & Co., Eisai, GlaxoSmithKline
Key drugs: Keytruda, Lenvima, Jemperli
